Opinion|Videos|June 25, 2024
Key Takeaways on mBC and eBC
Key opinion leaders (KOLs) provide key takeaways on metastatic breast cancer and early breast cancer, emphasizing the enthusiasm surrounding recent advances in the field and the potential for improved patient outcomes.
Advertisement
Episodes in this series
Video content above is prompted by the following question(s):
- What are your key takeaways on the evolving treatment landscape for metastatic breast cancer and early breast cancer?
Advertisement
Related to this article
October’s oncology coverage highlighted new treatment options in rectal, breast, and prostate cancers, alongside longer-term survival findings and concerns about reduced-frequency immunotherapy.
ESMO 2026 breast cancer updates show ribociclib boosts survival, while immunotherapy and extended endocrine therapy improve end points without longer overall survival.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Understanding Kratom: Pharmacology, Safety, and Regulation
2
How Stanford Pharmacists Help Close Heart Failure Therapy Gaps
3
GLP-1s and Obesity Care: Cardiorenal Outcomes, Prescribing Considerations, and Access Barriers
4
GLP-1 Receptor Agonists and Cancer: Considerations for Specialty Pharmacists
5